Chemoinformatics and Bioinformatics in the Pharmaceutical Sciences brings together two very important fields in pharmaceutical sciences that have been mostly seen as diverging from each other: chemoinformatics and bioinformatics. As developing drugs is an expensive and lengthy process, technology can improve the cost, efficiency and speed at which new drugs can be discovered and tested. This book presents some of the growing advancements of technology in the field of drug development and how the computational approaches explained here can reduce the financial and experimental burden of the drug discovery process. This book will be useful to pharmaceutical science researchers and students who need basic knowledge of computational techniques relevant to their projects. Bioscientists, bioinformaticians, computational scientists, and other stakeholders from industry and academia will also find this book helpful.

​This book presents drug repurposing strategies to combat infectious diseases and cancer. It discusses key experimental and in silico approaches for modern drug repositioning, including signature matching, molecular docking, genome-wide associated studies, and network-based approaches aided by artificial intelligence. Further, the book presents various computational and experimental strategies for better understanding disease mechanisms and identify repurposed drug candidates for personalized pharmacotherapy. It also explores the databases for drug repositioning, summarizes the approaches taken for drug repositioning, and highlights and compares their characteristics and challenges. Towards the end, the book discusses challenges and limitations encountered in computational drug repositioning.

Aim of the present work was to carry out pharmacoepidemiological survey of some marketed polyherbal antidiabetic formulations through the questionnaires evaluating the views of doctors, patients, pharmacists and herbal industries. We then evaluated some phytochemical and analytical quality control parameters for some selected herbal preparations and developed HPTLC methods for quantitative estimation of biomarkers like curcumin, charantin and swetiamarin in some polyherbal formulations like Diabecon(r) (The Himalaya Drug Company, Bangalore), Mersina(r) (J & J Dechane Lab. Pvt. Ltd., Hyderabad) and Madhuripu(r) (LVG, Ahmedabad). The formulation Mersina was finally also evaluated pharmacologically in diabetic patient

Acne is one of the major manifestations in patient with PCOS. Although acne is detected only in about 23-35% of patients with PCOS, some studies show a high prevalence of PCOS in acne patients. Acne has an overall prevalence in women of about 12%, tends to persist till menopause, and then declines with age.Hyperinsulinemia, insulin resistance and hyperandrogenemia are some endocrine findings in adults with PCOS.Hyperandrogenism characterized clinically as Acne, Hirsutism, Androgenic alopecia and/or chronic anovulation in the absence of specific adrenal and/or pituitary disease. Clinically, diagnosed woman with PCOS has higher risk for infertility, dysfunctional bleeding, endometrial carcinoma, obesity, type 2 diabetes mellitus, dyslipidemia, hypertension, and possibly cardiovascular disease. So to prevent risk factors associated with PCOS, it has to be diagnosed and treated earlier. Female with Acne are unaware that they may suffer from PCOS. So Acne patients coming to dermatologist must be diagnosed for PCOS, so that they can be treated at early stage and risk factors of PCOS can be prevente